Crohns Disease Treatment Market – By Treatment (Medication {Anti-inflammatory Agents, Immunosuppressants, Antibiotics, Antipyretics}, Nutritional Therapy, Surgery), Dosage Form (Oral, Parenteral), Age Group, End-use, Global Forecast 2024 ­ 2032

Crohn’s Disease Treatment Market Size

Crohn’s Disease Treatment Market size was valued at USD 13.3 billion in 2023 growing at a CAGR of 4% from 2024 to 2032. One of the primary drivers for the growth is the increasing prevalence of Chron’s disease.
 

For instance, as per the report published by Crohn’s & Colitis Foundation of America it has been reported that approximately 1.6 million Americans currently have Crohn’s disease or ulcerative colitis. As many as 70,000 new cases of inflammatory bowel diseases (IBD) are diagnosed in the U.S. each year. Therefore, the advancement in diagnostic technologies enable earlier and more accurate detection of Crohn's disease. Thus, the rapid increase in the prevalence of Crohn’s disease globally is the major factor that is expanding the demand for effective treatment option, thereby driving the market growth. Further, the increasing awareness and improved diagnostic techniques have led to a higher diagnosis rate which enable for increasing number of patients seeking treatment, thereby contributing to the market growth.
 

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. Treatment for Crohn’s disease can include the use of medication, alterations in diet and nutrition, and surgical procedures to repair or remove affected portions of the GI tract. Medication treating Crohn’s disease is designed to suppress the immune system’s abnormal inflammatory response that is causing the symptoms.
 

Crohn’s Disease Treatment Market Trends

The rising prevalence of Crohn's disease significantly fuels the growth of the Crohn's disease treatment industry. As more individuals are diagnosed with this chronic inflammatory condition, the demand for effective treatments and management strategies escalates. This surge in patient numbers drives pharmaceutical companies to invest in research and development, leading to the introduction of advanced biologics, immunosuppressants, and small molecule drugs.

For instance, as per the research conducted by Crohn’s & Colitis UK in 2022 it has been reported that 1 in every 123 people in the UK have either Crohn’s disease or ulcerative colitis. This amounts to a total of nearly half a million people in the UK living with IBD. Thus, the rising prevalence of Crohn’s disease globally increases the demand for effective treatment option, that will boost the market for Crohn’s disease treatment.
 

Crohn’s Disease Treatment Market Analysis

Based on the treatment, the global market is classified into medication, nutritional therapy, and surgery. The medication segment dominated the market with revenue of USD 7.2 billion in 2023.
 

• The introduction of biosimilars has enabled cost-effective alternatives which as increased accessibility. Therefore, the development of new biologic therapies and biosimilars has significantly improved treatment outcomes for Crohn's disease, thereby driving the growth of the medication segment in market.
   
• Moreover, advancement in drug delivery systems such as extended-release formulations, and oral delivery methods, enhance patient adherence and convenience. Improved formulations can lead to better disease management and patient outcomes, thereby boosting the segmental growth for Crohn’s disease treatment.
   
• Furthermore, ongoing research into the pathophysiology of Crohn's disease and the development of novel therapeutic targets contribute to the introduction of innovative medications. Thus, continuous R&D efforts ensure a pipeline of new drugs, driving future growth in the market.

Based on the dosage form, the global Crohn’s disease treatment market is classified into oral and parenteral. The parenteral segment dominated the market with market share of 59.8% in 2023.
 

• Few patients with Crohn's disease may have difficulty swallowing or may experience issues with absorption due to gastrointestinal complications. Therefore, parenteral formulations bypass these issues, ensuring patients receive the necessary medication reliably.
   
• Also, parenteral formulations offer higher bioavailability and faster onset of action compared to oral formulations. This is crucial in managing acute symptoms and achieving rapid therapeutic effects in Crohn's disease patients.
   
• Furthermore, parenteral administration allows healthcare providers to closely monitor drug levels and adjust dosages more precisely, which is critical in managing the unpredictable and variable nature of Crohn's disease, thereby fuelling the market growth.
   

Based on age group, the Crohn’s disease treatment market is classified into pediatric, adult, and geriatric. The adult segment is expected to reach USD 8.7 billion by 2032.
 

• Crohn's disease commonly manifests in late adolescence and early adulthood. This results in a higher number of young adults requiring treatment. Also, changes in lifestyle and dietary habits among adults such as increased consumption of processed foods, smoking, and stress, are linked to a higher risk of developing Crohn's disease. Thus, these lifestyle factors contribute to the growing number of adult patients seeking treatment.
   
• Furthermore, increased awareness and education about Crohn's disease among adults lead to higher diagnosis rates and more proactive management of the disease, thereby augmenting the market growth.
   

Based on end-use, the Crohn’s disease treatment market is classified into hospitals & clinics, homecare settings, and other end-users. The hospitals & clinics segment is expected to exhibit 4.3% CAGR between 2024 - 2032.
 

• Hospitals and clinics often have access to sophisticated diagnostic tools and technologies, enabling accurate and early diagnosis of Crohn's disease. This attracts patients seeking precise diagnosis and effective treatment plans. Hospitals and academic medical centers often conduct clinical trials for new Crohn's disease treatments. Patients may seek out these institutions to gain access to cutting-edge therapies.
   
• Furthermore, hospitals and clinics often provide integrated care facilities where various aspects of Crohn's disease management including medication, surgery, dietary management and psychological support are available. This convenience attracts patients looking for comprehensive care, thereby supplementing the segmental growth.

In 2023, North America secured a substantial market share of 44.2% in the global Crohn’s disease treatment market and is expected to dominate throughout the forecast period.
 

• North America has a strong presence of major pharmaceutical and biotechnology companies that are driving innovation and development of new treatment options for Crohn’s disease. These companies invest heavily in R&D activities to bring new biologics and other therapies to the market.
   
• In addition, the well-established healthcare infrastructure in the U.S. supports widespread diagnosis and treatment options for Crohn's disease patients. This includes access to specialized care, diagnostic tools, and a variety of treatment modalities, thereby contributing the growth of the market in the U.S.
   
• Ongoing developments in medical technology, including advancements in biologics, targeted therapies, and personalized medicine, have improved treatment outcomes and expanded the range of therapeutic options available to patients. Thus, the aforementioned factor contributed to North America's dominance in the market.
   

Germany to experience the highest growth rate in the Europe Crohn’s disease treatment market.
 

• Supportive government policies and initiatives aimed at improving patient outcomes and access to innovative therapies drive the market growth. Also, reimbursement policies for expensive biologic treatments are particularly influential in Germany.
   
• Therefore, Germany boasts a well-developed healthcare infrastructure, including specialized clinics and hospitals offering advanced treatments for inflammatory bowel diseases like Crohn's. Access to healthcare and reimbursement policies also play a significant role in market growth.
   

The Asia Pacific Crohn’s disease treatment market is expected to grow with a significant CAGR of 4.4% during the forecast period.
 

• Urbanization often leads to lifestyle changes such as diet and stress levels, which are known to influence the prevalence and severity of Crohn's disease. As urbanization continues in the region, the incidence of Crohn's disease may rise, thereby driving the market growth.
   
• Moreover, pharmaceutical companies and research institutions are investing in clinical trials and research studies focused on Crohn's disease within the Asia-Pacific region. This contributes to the availability of new treatments and therapies, thus fostering the regional market growth.
   

Crohn’s Disease Treatment Market Share

The Crohn’s disease treatment industry is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts are aimed at enhancing their product offerings, expanding their geographic reach, and investing in advanced technologies to strengthen their market presence.
 

Crohn’s Disease Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the Crohn’s disease treatment industry are as mentioned below:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Biogen
• Boehringer Ingelheim GmbH
• Bristol Myerr Squibb
• Eli Lilly and Company
• Janssen Pharmaceuticals (Johnson & Johnson)
• Merck & Co. Inc
• Novartis AG
• Pfizer, Inc.
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Industries Limited
• Viatris Inc. (Mylan N.V.)
   

Crohn’s Disease Treatment Industry News:

• In June 2024, AbbVie announced the U.S. Food and Drug Administration (FDA) approval of SKYRIZI (risankizumab-rzaa) for adults with moderate to severe ulcerative colitis and moderate to severe Crohn's disease. This launch strategy is expected to help the company to expand its product offerings.
   
• In October 2023, Sanofi and Teva Pharmaceuticals, announced a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease. This approval aimed to broaden the treatment availability, complementing existing therapies for Crohn’s disease.
   

The Crohn’s disease treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Medication
  • Anti-inflammatory agents
  • Immunosuppressants
  • Antibiotics and antipyretics
  • Other medications
• Nutritional therapy
• Surgery

Market, By Dosage Form

• Oral
• Parenteral

Market, By Age Group

• Pediatric
• Adult
• Geriatric

Market, By End-use

• Hospitals & clinics
• Homecare settings
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa